DE69735090T2 - Neurotrophin antagoniste zur behandlung von der epilepsie, alzheimer'schen krankheit und schmerzen - Google Patents
Neurotrophin antagoniste zur behandlung von der epilepsie, alzheimer'schen krankheit und schmerzen Download PDFInfo
- Publication number
- DE69735090T2 DE69735090T2 DE69735090T DE69735090T DE69735090T2 DE 69735090 T2 DE69735090 T2 DE 69735090T2 DE 69735090 T DE69735090 T DE 69735090T DE 69735090 T DE69735090 T DE 69735090T DE 69735090 T2 DE69735090 T2 DE 69735090T2
- Authority
- DE
- Germany
- Prior art keywords
- isoquinoline
- alkyl
- dioxo
- nitro
- tetrahydrobenzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000011282 treatment Methods 0.000 title claims description 13
- 208000002193 Pain Diseases 0.000 title description 11
- 230000036407 pain Effects 0.000 title description 10
- 239000005557 antagonist Substances 0.000 title description 2
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 45
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 17
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 125000001769 aryl amino group Chemical group 0.000 claims abstract description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 3
- -1 C 1 -C 4 alkoxy Chemical group 0.000 claims description 40
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 40
- XJHABGPPCLHLLV-UHFFFAOYSA-N benzo[de]isoquinoline-1,3-dione Chemical compound C1=CC(C(=O)NC2=O)=C3C2=CC=CC3=C1 XJHABGPPCLHLLV-UHFFFAOYSA-N 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 229910004013 NO 2 Inorganic materials 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- XNPLAGSBSNNWSD-UHFFFAOYSA-N (1,3-dioxo-4,4a-dihydrobenzo[i]isoquinolin-2-yl) acetate Chemical compound C1=CC=C2C=CC=CC32C1CC(=O)N(OC(=O)C)C3=O XNPLAGSBSNNWSD-UHFFFAOYSA-N 0.000 claims description 7
- 206010015037 epilepsy Diseases 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- BSMLNRFWSYKIEP-UHFFFAOYSA-N 2-(dimethylamino)-5-nitro-4,4a-dihydrobenzo[i]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC=C2C=CC=CC32C1CC(=O)N(N(C)C)C3=O BSMLNRFWSYKIEP-UHFFFAOYSA-N 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
- LIMGTTOBSVFWHF-UHFFFAOYSA-N 6-phenylsulfanyl-2-(2-pyridin-2-ylethyl)-4,4a-dihydrobenzo[i]isoquinoline-1,3-dione Chemical compound C1=C2C=CC=CC32C(=O)N(CCC=2N=CC=CC=2)C(=O)CC3C=C1SC1=CC=CC=C1 LIMGTTOBSVFWHF-UHFFFAOYSA-N 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- FOHVEYFTPNIRHA-UHFFFAOYSA-N 2-(2-aminophenyl)-4,4a-dihydrobenzo[i]isoquinoline-1,3-dione Chemical compound NC1=CC=CC=C1N1C(=O)C23C=CC=CC3=CC=CC2CC1=O FOHVEYFTPNIRHA-UHFFFAOYSA-N 0.000 claims description 4
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 claims description 4
- PCHTYOFNOJYYNQ-UHFFFAOYSA-N C1=CC=C2C=CC=CC32C1CC(=O)N(CC)C3=O Chemical compound C1=CC=C2C=CC=CC32C1CC(=O)N(CC)C3=O PCHTYOFNOJYYNQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- HFCAHBWZCRSZEE-UHFFFAOYSA-N 2-(1h-benzimidazol-2-yl)-4,4a-dihydrobenzo[i]isoquinoline-1,3-dione Chemical compound C1=CC=C2NC(N3C(=O)C45C=CC=CC5=CC=CC4CC3=O)=NC2=C1 HFCAHBWZCRSZEE-UHFFFAOYSA-N 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000007914 intraventricular administration Methods 0.000 claims description 3
- VCICXIUPVYISNU-UHFFFAOYSA-N n-[2-(1,3-dioxo-4,4a-dihydrobenzo[i]isoquinolin-2-yl)phenyl]-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=CC=CC=C1N1C(=O)C23C=CC=CC3=CC=CC2CC1=O VCICXIUPVYISNU-UHFFFAOYSA-N 0.000 claims description 3
- 230000002981 neuropathic effect Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 2
- XQFSDWLIFRTQQP-UHFFFAOYSA-N 6-bromo-2-(dimethylamino)-4,4a-dihydrobenzo[i]isoquinoline-1,3-dione Chemical compound C1=C(Br)C=C2C=CC=CC32C1CC(=O)N(N(C)C)C3=O XQFSDWLIFRTQQP-UHFFFAOYSA-N 0.000 claims description 2
- UUIQMZJEGPQKFD-UHFFFAOYSA-N Methyl butyrate Chemical compound CCCC(=O)OC UUIQMZJEGPQKFD-UHFFFAOYSA-N 0.000 claims description 2
- 229910000071 diazene Inorganic materials 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- CPPDVCCRUHPOSK-UHFFFAOYSA-N 2-isoquinolin-1-ylacetic acid Chemical compound C1=CC=C2C(CC(=O)O)=NC=CC2=C1 CPPDVCCRUHPOSK-UHFFFAOYSA-N 0.000 claims 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 108010025020 Nerve Growth Factor Proteins 0.000 abstract description 61
- 102000007072 Nerve Growth Factors Human genes 0.000 abstract description 36
- 230000000694 effects Effects 0.000 abstract description 16
- 230000001404 mediated effect Effects 0.000 abstract description 11
- 230000014511 neuron projection development Effects 0.000 abstract description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 4
- 230000004770 neurodegeneration Effects 0.000 abstract description 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 25
- 229940053128 nerve growth factor Drugs 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 15
- 230000027455 binding Effects 0.000 description 13
- 241000700159 Rattus Species 0.000 description 11
- 210000002569 neuron Anatomy 0.000 description 11
- 108090000099 Neurotrophin-4 Proteins 0.000 description 10
- 208000004454 Hyperalgesia Diseases 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 8
- 210000005036 nerve Anatomy 0.000 description 8
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 7
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 7
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229940126062 Compound A Drugs 0.000 description 5
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 5
- 102000004230 Neurotrophin 3 Human genes 0.000 description 5
- 108090000742 Neurotrophin 3 Proteins 0.000 description 5
- 102000003683 Neurotrophin-4 Human genes 0.000 description 5
- 102100033857 Neurotrophin-4 Human genes 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000004031 neuronal differentiation Effects 0.000 description 5
- 229940032018 neurotrophin 3 Drugs 0.000 description 5
- 229940097998 neurotrophin 4 Drugs 0.000 description 5
- 108090000095 Neurotrophin-6 Proteins 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000006576 neuronal survival Effects 0.000 description 3
- 239000003900 neurotrophic factor Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000003104 tissue culture media Substances 0.000 description 3
- 102000015533 trkA Receptor Human genes 0.000 description 3
- 108010064884 trkA Receptor Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101150111783 NTRK1 gene Proteins 0.000 description 2
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000003855 balanced salt solution Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 210000000609 ganglia Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000002248 primary sensory neuron Anatomy 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000020341 sensory perception of pain Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 102000015534 trkB Receptor Human genes 0.000 description 2
- 108010064880 trkB Receptor Proteins 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GBHCABUWWQUMAJ-UHFFFAOYSA-N 2-hydrazinoethanol Chemical compound NNCCO GBHCABUWWQUMAJ-UHFFFAOYSA-N 0.000 description 1
- ATVJJNGVPSKBGO-UHFFFAOYSA-N 3,4-dihydro-2h-thiopyran Chemical compound C1CSC=CC1 ATVJJNGVPSKBGO-UHFFFAOYSA-N 0.000 description 1
- OUBANBKTBRGNLP-UHFFFAOYSA-N 3-(1-morpholin-4-yl-5-nitro-2,3,4,4a-tetrahydrobenzo[i]isoquinolin-1-yl)-3-oxopropanal Chemical compound [O-][N+](=O)C1=CC=C2C=CC=CC22C1CCNC2(C(=O)CC=O)N1CCOCC1 OUBANBKTBRGNLP-UHFFFAOYSA-N 0.000 description 1
- DYWWDZQRZYAPHQ-UHFFFAOYSA-N 3-benzoyl-4-ethyl-4-methyl-2-phenyl-1,3-oxazolidin-5-one Chemical compound O1C(=O)C(CC)(C)N(C(=O)C=2C=CC=CC=2)C1C1=CC=CC=C1 DYWWDZQRZYAPHQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JGFBQFKZKSSODQ-UHFFFAOYSA-N Isothiocyanatocyclopropane Chemical compound S=C=NC1CC1 JGFBQFKZKSSODQ-UHFFFAOYSA-N 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GRSMWKLPSNHDHA-UHFFFAOYSA-N Naphthalic anhydride Chemical compound C1=CC(C(=O)OC2=O)=C3C2=CC=CC3=C1 GRSMWKLPSNHDHA-UHFFFAOYSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- YRRFBANPGRXQNJ-UHFFFAOYSA-M acetyl(trimethyl)azanium;bromide Chemical compound [Br-].CC(=O)[N+](C)(C)C YRRFBANPGRXQNJ-UHFFFAOYSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000004855 amber Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- PWLNAUNEAKQYLH-UHFFFAOYSA-N butyric acid octyl ester Natural products CCCCCCCCOC(=O)CCC PWLNAUNEAKQYLH-UHFFFAOYSA-N 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 208000022371 chronic pain syndrome Diseases 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- HEJDFHJICJPEMK-UHFFFAOYSA-N n-[2-(1,3-dioxo-4,4a-dihydrobenzo[i]isoquinolin-2-yl)-4,5-dimethylphenyl]-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=CC(C)=C(C)C=C1N1C(=O)C23C=CC=CC3=CC=CC2CC1=O HEJDFHJICJPEMK-UHFFFAOYSA-N 0.000 description 1
- 230000019569 negative regulation of cell differentiation Effects 0.000 description 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000005015 neuronal process Effects 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 102000047459 trkC Receptor Human genes 0.000 description 1
- 108010064892 trkC Receptor Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9621902 | 1996-10-21 | ||
| GBGB9621902.7A GB9621902D0 (en) | 1996-10-21 | 1996-10-21 | Neurotrophin antagonist compositions |
| GB9710904 | 1997-05-27 | ||
| GBGB9710904.5A GB9710904D0 (en) | 1997-05-27 | 1997-05-27 | Neurotropin antagonist compositions |
| PCT/CA1997/000779 WO1998017278A1 (en) | 1996-10-21 | 1997-10-20 | Neurotrophin antagonist compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69735090D1 DE69735090D1 (de) | 2006-04-06 |
| DE69735090T2 true DE69735090T2 (de) | 2006-09-14 |
Family
ID=26310264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69735090T Expired - Fee Related DE69735090T2 (de) | 1996-10-21 | 1997-10-20 | Neurotrophin antagoniste zur behandlung von der epilepsie, alzheimer'schen krankheit und schmerzen |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20020169182A1 (enExample) |
| EP (1) | EP0930883B1 (enExample) |
| JP (1) | JP2001503397A (enExample) |
| KR (1) | KR20000052691A (enExample) |
| AT (1) | ATE315397T1 (enExample) |
| AU (1) | AU728523C (enExample) |
| BR (1) | BR9712424A (enExample) |
| CA (1) | CA2268450C (enExample) |
| DE (1) | DE69735090T2 (enExample) |
| DK (1) | DK0930883T3 (enExample) |
| ES (1) | ES2257768T3 (enExample) |
| IL (1) | IL129475A0 (enExample) |
| NZ (1) | NZ335291A (enExample) |
| WO (1) | WO1998017278A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2268450C (en) | 1996-10-21 | 2008-08-05 | Allelix Biopharmaceuticals, Inc. | Neurotrophin antagonist compositions |
| BR9915648A (pt) * | 1998-11-25 | 2001-08-14 | Merck Patent Gmbh | Benzo [de] isoquinolina-1,3-dionas substituìdas |
| EP1133475A1 (en) * | 1998-11-25 | 2001-09-19 | MERCK PATENT GmbH | Substituted benzo de]isoquinoline-1,3-diones |
| US6492380B1 (en) | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
| US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| FR2807660A1 (fr) * | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| US7255860B2 (en) | 2002-10-08 | 2007-08-14 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody |
| EP1556083B1 (en) | 2002-10-08 | 2011-02-02 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by admisnistering an antibody against nerve growth factor and compositions containing the same |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| EP2270048B1 (en) | 2002-12-24 | 2015-11-11 | Rinat Neuroscience Corp. | Anti-NGF antibodies and methods using same |
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| KR20050111598A (ko) | 2003-02-19 | 2005-11-25 | 리나트 뉴로사이언스 코퍼레이션 | 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물 |
| FR2862968B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique |
| FR2862967B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique |
| AU2005243247B2 (en) | 2004-04-07 | 2012-03-01 | Regents Of The University Of Minnesota | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
| GB0419850D0 (en) * | 2004-09-07 | 2004-10-13 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| BRPI0615930A2 (pt) * | 2005-09-15 | 2016-08-23 | Painceptor Pharma Corp | métodos de modular a interação de uma neurotrofina e um receptor de neurotrofina, de tratar dor em um indivíduo, de tratar distúrbio inflamatório em um indivíduo, de tratar um distúrbio neurológico em um indivíduo, e de tratar uma doença ou distúrbio associado aos sistemas geniturinário e/ou gastrointestinal de um indivíduo, e, composto |
| US20090082368A1 (en) * | 2007-09-24 | 2009-03-26 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
| FR2953839A1 (fr) * | 2009-12-14 | 2011-06-17 | Sanofi Aventis | Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75 |
| WO2012024650A2 (en) | 2010-08-19 | 2012-02-23 | Abbott Laboratories | Anti-ngf antibodies and their use |
| EP2606894A1 (en) | 2011-12-20 | 2013-06-26 | Sanofi | Novel therapeutic use of p75 receptor antagonists |
| JP6629069B2 (ja) | 2012-06-06 | 2020-01-15 | ゾエティス・エルエルシー | イヌ化抗ｎｇｆ抗体およびその方法 |
| MX2020009526A (es) | 2018-03-12 | 2020-10-28 | Zoetis Services Llc | Anticuerpos anti-ngf y metodos de estos. |
| WO2022018679A1 (en) * | 2020-07-24 | 2022-01-27 | Jawaharlal Nehru Centre For Advanced Scientific Research | Naphthalene monoimide compounds and methods thereof |
| US20230348608A1 (en) | 2022-04-27 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Treatment Of Arthropathy Based Upon Stratification Of Osteoarthritis Polygenic Risk Score |
| AU2024238259A1 (en) | 2023-03-17 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Proteomic risk score for osteoarthritis (oa) |
| WO2026054762A1 (en) | 2024-09-05 | 2026-03-12 | Regeneron Pharmaceuticals, Inc. | Proteomic risk score for adjudicated arthropathy (aa) |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US525841A (en) * | 1894-09-11 | Baling-press | ||
| US627129A (en) * | 1899-06-20 | Collar-edge-ironing machine | ||
| US3821383A (en) * | 1972-07-10 | 1974-06-28 | Ayerst Mckenna & Harrison | Compositions for and a method of treating diabetic complications |
| US4006238A (en) | 1975-08-28 | 1977-02-01 | E. R. Squibb & Sons, Inc. | Use of 2-(hydroxyalkyl)-1H-benz[de]isoquinoline-1,3(2H)-diones as anti-allergy agents |
| ES459497A1 (es) | 1977-06-04 | 1978-04-16 | Made Labor Sa | Un metodo para la preparacion industrial de naftalimidas y sus derivados. |
| US4254109A (en) * | 1979-11-08 | 1981-03-03 | Ayerst, Mckenna & Harrison Inc. | 1H-Benz[de]isoquinoline-2(3H)-acetic acid derivatives |
| RU2051677C1 (ru) * | 1982-02-10 | 1996-01-10 | Украинский научно-исследовательский институт эндокринологии и обмена веществ | Средство для профилактики и лечения диабетических осложнений, ангиопатий, нейропатий, катаракты |
| US5183821A (en) | 1983-09-19 | 1993-02-02 | Laboratories Knoll, S.A. | Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors |
| IT1214618B (it) * | 1985-06-27 | 1990-01-18 | I P A International Pharmaceut | Composti e composizioni farmaceutiche per la terapia di retinopatie e neuropatie diabetiche. |
| DE3635711A1 (de) | 1986-10-21 | 1988-04-28 | Knoll Ag | 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung |
| DE3707652A1 (de) * | 1987-03-10 | 1988-09-22 | Knoll Ag | Verwendung von benzo(de)isochinolin-1,3-dionen zur herstellung von arzneimitteln |
| DE3707651A1 (de) | 1987-03-10 | 1988-09-22 | Knoll Ag | Bis-naphthalimide, ihre herstellung und verwendung |
| US5420137A (en) | 1989-07-11 | 1995-05-30 | Knoll Ag | Amonafide salts |
| US5356906A (en) * | 1989-10-27 | 1994-10-18 | The Du Pont Merck Pharmaceutical Company | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis |
| CA2030129A1 (en) | 1989-11-29 | 1991-05-30 | Thomas Saupe | 1,8-napthalenedicarboximides as antidotes |
| US5342942A (en) | 1992-06-09 | 1994-08-30 | Warner-Lambert Company | Pyrazoloquinazolone derivatives as neurotrophic agents |
| DE4232739A1 (de) | 1992-09-30 | 1994-03-31 | Knoll Ag | Neue asymmetrisch substituierte bis-Naphthalimide |
| IL110460A (en) | 1993-08-18 | 2001-01-11 | Basf Ag | Bis-naphthalimides, their preparation and pharmaceutical compositions containing them |
| US6291247B1 (en) | 1994-05-11 | 2001-09-18 | Queen's University At Kingston | Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity |
| GB9616105D0 (en) | 1996-07-31 | 1996-09-11 | Univ Kingston | TrkA binding site of NGF |
| CA2268450C (en) | 1996-10-21 | 2008-08-05 | Allelix Biopharmaceuticals, Inc. | Neurotrophin antagonist compositions |
| CA2319680C (en) | 1997-02-07 | 2010-04-20 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| WO1998052919A1 (en) | 1997-05-21 | 1998-11-26 | Japan Tobacco Inc. | Phthalimide derivatives and pharmaceutical containing said derivatives |
| WO2000000472A1 (en) | 1998-06-30 | 2000-01-06 | Du Pont Pharmaceuticals Company | 5-ht7 receptor antagonists |
| JP3357662B2 (ja) | 1998-07-03 | 2002-12-16 | 大鵬薬品工業株式会社 | ナフタルイミドベンズアミド誘導体 |
| US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| US6492380B1 (en) | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
-
1997
- 1997-10-20 CA CA002268450A patent/CA2268450C/en not_active Expired - Fee Related
- 1997-10-20 ES ES97909098T patent/ES2257768T3/es not_active Expired - Lifetime
- 1997-10-20 DK DK97909098T patent/DK0930883T3/da active
- 1997-10-20 BR BR9712424-9A patent/BR9712424A/pt not_active Application Discontinuation
- 1997-10-20 AU AU46968/97A patent/AU728523C/en not_active Ceased
- 1997-10-20 AT AT97909098T patent/ATE315397T1/de not_active IP Right Cessation
- 1997-10-20 IL IL12947597A patent/IL129475A0/xx not_active IP Right Cessation
- 1997-10-20 JP JP51875698A patent/JP2001503397A/ja not_active Ceased
- 1997-10-20 DE DE69735090T patent/DE69735090T2/de not_active Expired - Fee Related
- 1997-10-20 EP EP97909098A patent/EP0930883B1/en not_active Expired - Lifetime
- 1997-10-20 KR KR1019990703479A patent/KR20000052691A/ko not_active Withdrawn
- 1997-10-20 NZ NZ335291A patent/NZ335291A/en unknown
- 1997-10-20 WO PCT/CA1997/000779 patent/WO1998017278A1/en not_active Ceased
-
2001
- 2001-01-11 US US09/758,917 patent/US20020169182A1/en not_active Abandoned
-
2005
- 2005-07-13 US US11/179,610 patent/US7291629B2/en not_active Expired - Fee Related
-
2007
- 2007-09-28 US US11/905,406 patent/US20080287484A1/en not_active Abandoned
-
2009
- 2009-04-28 US US12/453,032 patent/US20090215815A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE315397T1 (de) | 2006-02-15 |
| EP0930883B1 (en) | 2006-01-11 |
| AU728523C (en) | 2001-08-09 |
| KR20000052691A (ko) | 2000-08-25 |
| US20020169182A1 (en) | 2002-11-14 |
| US7291629B2 (en) | 2007-11-06 |
| US20090215815A1 (en) | 2009-08-27 |
| US20080287484A1 (en) | 2008-11-20 |
| AU728523B2 (en) | 2001-01-11 |
| NZ335291A (en) | 2001-02-23 |
| WO1998017278A1 (en) | 1998-04-30 |
| BR9712424A (pt) | 2001-11-20 |
| JP2001503397A (ja) | 2001-03-13 |
| CA2268450A1 (en) | 1998-04-30 |
| EP0930883A1 (en) | 1999-07-28 |
| AU4696897A (en) | 1998-05-15 |
| IL129475A0 (en) | 2000-02-29 |
| DE69735090D1 (de) | 2006-04-06 |
| DK0930883T3 (da) | 2006-05-22 |
| ES2257768T3 (es) | 2006-08-01 |
| US20050250807A1 (en) | 2005-11-10 |
| CA2268450C (en) | 2008-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2268450C (en) | Neurotrophin antagonist compositions | |
| DE2623567C2 (de) | Thienopyridinderivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittelzubereitungen | |
| DE69634691T2 (de) | Tricyclische amid-derivate verwendbar als g-protein funktion inhibitoren und für die behandlung von proliferativen erkrankungen | |
| DE69333874T2 (de) | Verwendung von vier K-252a Derivaten | |
| DE3876400T2 (de) | Aminosaeure-imid-derivate, ihre verwendung und diese enthaltende medizinische zusammensetzungen. | |
| DE69729798T2 (de) | Therapeutische behandlung von vegf-bedingten augenkrankheiten | |
| DE69507112T2 (de) | Verwendung eines Serotoninagonisten in Kombination mit einem Tachykininrezeptorantagonisten zur Herstellung eines Arzneimittels zur Prävention oder Behandlung der Migräne | |
| DE69625877T2 (de) | Verwendung von 5-HT1A Rezeptor-Liganden zur Behandlung des Glaukoms | |
| DE69811492T2 (de) | Benzonaphthyridine | |
| DE69332048T2 (de) | Verfahren zur senkung des augeninnendrucks im auge von säugern unter anwendung von muskarinantagonisten | |
| DE69027180T2 (de) | 4-Acylaminopyridin-Derivate | |
| DE69202166T2 (de) | Verwendung von Tetrahydrothienopyridinderivate als Angiogenese-Inhibitoren. | |
| DE10005302A1 (de) | Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate | |
| DE60009287T2 (de) | Neuartige isoquinolin-derivate oder salze davon | |
| DE69826881T2 (de) | Neue indolcarboxamide, pharmazeutische zusammensetzungen und methoden zur hemmung von calpain | |
| US3998843A (en) | Quaternary ammonium compounds | |
| DE60209886T2 (de) | Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen | |
| DE69725713T2 (de) | Spiro(cyclopent(b)indol-piperidine) und n-phenylhydrazon-zwischenprodukte zu deren herstellung, beide als acetylcholinesterase- und mao-inhibitoren | |
| DE69730232T2 (de) | Arylphtalazine antagonisten vonexitatonischen amino saüre rezeptoren | |
| DE69709869T2 (de) | BENZO[g]CHINOLIN DERIVATE | |
| DE602005005843T2 (de) | 4 ä(2,4-dichloro-5-methoxyphenyl)aminoü-6-alkoxy-7-ethynyl-3-chinolincarbonitrile zur behandlung von ischämie | |
| DE69738349T2 (de) | Anthranilsäurediamid-derivate, ihre herstellung und pharmazeutische verwendung als antigastrinmittel | |
| DE69532963T2 (de) | Verwendung von 4-acylaminopyridin derivaten zur Herstellung eines Medikaments für die Behandlung von zerebrovaskulären Erkrankungen | |
| DE19703985A1 (de) | Tetrahydroisochinolinderivate | |
| DE60104822T2 (de) | Pseudopolymorph von (-)-cis-2-(2-chlorphenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-on hydrochlorid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |